This project (2018-1-ES01-KA203-050606) has been funded with support from the European Commission.
This web site reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

This project has been funded with support from the European Commission.
This web site reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

Select language   >   EL ES IT RO EN

Digital Objects

Back to Digital Objects

COVID-19 Vaccine: A comprehensive status report


Place where the object is located
COVID-19 Vaccine: A comprehensive status report – a scientific article that outlines platforms for COVID-19 development, the clinical trials with their results and vaccine limitations.

Available on the website of the US National Library of Medicine National Institutes of Health
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423510/
Story of the object
Abstract: The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life.
Label
Author: Kaur SP, Gupta V.
Title: COVID-19 Vaccine: A comprehensive status report.
Publication: Virus Res. 2020 Oct 15;288:198114.
doi: 10.1016/j.virusres.2020.198114.
Epub 2020 Aug 13.
PMID: 32800805;
PMCID: PMC7423510.